Changes in Body Adiposity by Dual Probiotic Strains Positively Correlated With Changes in Lp-PLA2 Activity in Overweight Adults

Yonsei University120 enrolled

Overview

The objective was to evaluate the effect of the consumption of dual probiotic strains containing Lactobacillus curvatus (L. curvatus) HY7601 and Lactobacillus plantarum (L. plantarum) KY1032 on weight loss, body adiposity and inflammatory markers including lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in overweight subjects.

A randomized, double-blind, placebo-controlled study was conducted on 120 subjects with age between 20 and 65 years, nondiabetic (fasting blood glucose \<126 mg/dL and 2-hour blood glucose \<200 mg/dL), and overweight (25 kg/m2 ≤ body mass index (BMI) \< 30 kg/m2). Over a 12 week test period, the probiotic group consumed 2 g of powder twice a day containing L. curvatus HY7601 and L. plantarum KY1032, while the placebo group consumed the same product without probiotics for 12 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

120

Conditions

Overweight

Interventions

Probiotic groupDIETARY_SUPPLEMENT

The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.

Placebo groupDIETARY_SUPPLEMENT

The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age between 20 and 65 years * Nondiabetic (fasting blood glucose \<126 mg/dL and 2-hour blood glucose \<200 mg/dL) * Overweight (25 kg/m2 ≤ body mass index (BMI) \< 30 kg/m2) Exclusion Criteria: * Constant consumption of any probiotics products within 1 month before screening * Unstable body weight (body weight change \> 1 kg within 3 months before screening) * Hypertension * Type 2 diabetes * Cardiovascular disease * Cerebrovascular disease * Thyroid disease * Dietary supplementation within 6 months before screening * Pregnancy or breast-feeding * Medication affecting body weight, energy expenditure, glucose control or antibiotic treatment within 3 months before screening * Acute or chronic infections * Liver disease * Kidney disease * Gastrointestinal disease * Cancer * Medication or alcohol abuse * Any other acute or chronic disease requiring treatment

Outcomes

Primary Outcomes

Fat percentage by dual-energy x-ray absorptiometry (DEXA) at baseline and 12-week follow-up

Fat percentage (%)

Time frame: 12-week follow-up

Fat mass by DEXA at baseline and 12-week follow-up

Fat mass (g)

Time frame: 12-week follow-up

Lean body mass by DEXA at baseline and 12-week follow-up

Lean body mass (g)

Time frame: 12-week follow-up

Fat area by computed tomography (CT) at baseline and 12-week follow-up

Fat area (cm2) at levels of 1st lumbar (L1) vertebra and 4th lumbar (L4) vertebra

Time frame: 12-week follow-up

Secondary Outcomes

Total Cholesterol at baseline and 12-week follow-up

Total Cholesterol (mg/dL)

Time frame: 12-week follow-up

HDL Cholesterol at baseline and 12-week follow-up

HDL Cholesterol (mg/dL)

Time frame: 12-week follow-up

LDL Cholesterol at baseline and 12-week follow-up

LDL Cholesterol (mg/dL)

Time frame: 12-week follow-up

Triglyceride at baseline and 12-week follow-up

Triglyceride (mg/dL)

Time frame: 12-week follow-up

High sensitivity C-reactive protein (hs-CRP) at baseline and 12-week follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.